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Immunization with peptide P10, derived from gp43, and chemotherapy were used together in an attempt to
improve treatment of paracoccidioidomycosis and prevent relapses. The combined treatment showed an
additive protective effect when administered at 48 h or 30 days after intratracheal challenge. Its use is
recommended to improve regular chemotherapy and reduce the duration of treatment.
Extended periods of chemotherapy are often necessary to
treat paracoccidioidomycosis, with a significant frequency of
relapsing disease. In the present work we investigated the
combination of a vaccine of peptide P10 (10), derived from the
major diagnostic antigen gp43, and chemotherapy in mice in-
fected with a highly virulent human isolate of Paracoccidioides
brasiliensis, Pb18 (3). Antifungal drugs were tested in vitro to
determine the MIC by a modification of the method of
Shadomy et al. (9). MICs were in the range of values previously
reported for these fungi (4, 5, 7, 8).
To explore the effects of P10 immunization combined with
antifungal drug treatment, we used two different protocols
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TABLE 1. Cytokine levels in lungs of mice infected and subjected to chemotherapy and/or P10 vaccination after 48 h of infection
Treatment group
Cytokine level (pg/ml) at the indicated time (days) of infectiona
IL-4 IL-10 IL-12 IFN-
30 90 30 90 30 90 30 90
Sham 952  62 962  62.4 5,680  461 5,680  461 16,950  1,744 18,950  2,744 826  171 836  71
Adjuvant 988  111 854  70.7 4,997  488 4,221  726 15,021  1,012 10,121  1,014 911  111 914  102
Untreated 2,616  271 1,771  170.7 15,652  2,416 12,850  2,853 36,033  2,251 35,800  2,848 2,906  327 3,170  14
P10 1,640  250 1,065  163.3 12,525  1,611 8,500  628.3 46,233  3,767 31,600  2,707 4,396  352 4,515  77
Fluconazole 2,900  903 4,480  728# 23,600  2,608# 22,650  2,089# 37,566  4,564 95,100  5,433 5,446  333 4,400  669
Fluconazole  P10 2,850  534 2,530  314 16,633  2,609 14,400  2,565 56,600  3,786* 94,500  4,534 6,970  405* 6,280  854*
Ketoconazole 5,293  913# 2,055  249 25,500  2,500# 10,035  1,987# 47,566  4,429 43,950  2,767 5,610  355 2,885  390
Ketoconazole  P10 2,936  258 1,845  237 21,666  2,159 7,750  353 64,200  4,333* 52,100  1,989* 6,990  493* 3,955  577*
Itraconazole 2,893  273 2,170  328# 20,700  2,577# 11,950  2,433 58,000  2,873 48,765  2,888 2,643  399 1,750  295
Itraconazole  P10 3,486  705 1,130  284 15,613  608 13,050  2,453 49,500  3,786 48,600  4,121 4,313  256* 2,790  454*
Amphotericin B 1,546  274 1,345  106 16,100  2,458# 13,500  707 35,533  3,132 42,900  2,565 4,240  117 3,490  697
Amphotericin B  P10 2,486  405 2,295  389# 13,500  1,707 12,700  424 61,266  4,034* 46,300  2,765* 3,390  140 4,630  899*
Sulfamethoxazole 4,597  697# 3,145  863# 21,366  3,450 22,450  2,353# 52,200  2,878 33,700  2,555 3,603  361 2,505  548
Sulfamethoxazole  P10 3,026  587 1,265  345 19,333  2,577 13,000  1,221 51,427  3,777 61,266  4,324 4,560  311* 8,520  513
a Boldface indicates a predominat Th-1 or Th-2-like response according to the cytokines produced (IL-12/IFN- or IL-4/IL-10, respectively). *, statistically significant
difference (P  0.05) relative to mice treated only with the drug; #, statistically significant difference (P  0.05) relative to mice immunized with P10 and treated with
the drug. Values are means  standard deviations of measurements from 5 to 10 animals in each group. The whole experiment was repeated twice with reproducible
results.
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FIG. 1. Protocol 1 (treatment started 48 h after infection). CFU in organs from mice infected intratracheally with 3  105 yeast cells and
subjected to antifungal treatment combined or not with P10 immunization were determined. Mice were sacrificed after 30 () and 90 (■) days
of infection. Control mice were inoculated with phosphate-buffered saline, adjuvant-treated control mice were inoculated with CFA or IFA, and
P10-treated mice were immunized with the peptide. All groups of mice were infected with the same number of yeast cells. Experiments were carried
out in triplicate. Each bar represents the average counts and standard deviations in organs from 5 to 10 animals in each group. L, lung; S, spleen;
V, liver. The whole experiment was repeated twice with similar results. *, significant difference between the combined treatment and both P10
vaccine alone and drug treatment alone (P  0.05).
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FIG. 2. Protocol 2 (treatment started 30 days after infection). CFU in organs from mice infected intratracheally with 3  105 yeast cells and
subjected to antifungal treatment combined or not with P10 immunization were determined. Mice were sacrificed after 60 () and 120 (■) days
of infection. Control mice were inoculated with phosphate-buffered saline, adjuvant-treated control mice were inoculated with CFA or IFA, and
P10-treated mice were immunized with peptide. All groups of mice were infected with the same number of yeast cells. Experiments were carried
out in triplicate. Each bar represents the average counts and standard deviations in organs from 5 to 10 animals in each group. L, lung; S, spleen;
V, liver. *, significant differences between the combined treatment and both P10 vaccine alone and drug treatment alone (P  0.05).
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and 14 groups (n  10 each) of BALB/c mice (male, 6 to 8
weeks old) in each protocol. Controls included a group
infected with Pb18 only, another group infected and immu-
nized with P10, and a group infected and treated with
Freund’s adjuvant. Five groups of mice were infected and
treated with a single antifungal drug: fluconazole (Pfizer),
ketoconazole (Janssen-Cilag), itraconazole (Janssen-Cilag),
amphotericin B (Fungizone; Bristol Mayers Squibb), sulfa-
methoxazole (Sigma, St. Louis, MO), or trimethoprim-sulfa-
methoxazole (Bac-sulfitrin; Ducto). An additional five
groups were treated with antifungal drugs combined with
P10 immunization.
Drug treatment in the first and second protocols was
started after 48 h and 30 days, respectively, after intratra-
cheal infection with 3  105 yeast cells (10). The treatment
was continued for 30 days, during which groups of mice
received intraperitoneal doses of itraconazole (10 mg/kg),
fluconazole (10 mg/kg), ketoconazole (8 mg/kg), sulfa-
methoxazole (15 mg/kg), or trimethoprim-sulfamethoxazole
(3 and 15 mg/kg, respectively) every 24 h. Amphotericin B (1.5
mg/kg) was administered every 48 h. Immunization was carried
out weekly for 4 weeks with 20 g of P10 in complete Freund’s
adjuvant (CFA) once and in incomplete Freund’s adjuvant
(IFA) three times.
Analysis of CFU in organs was carried out after 30 and 90
days of infection under protocol 1. The pattern of CFU in
organs showed a significant reduction of fungi recovered from
animals either immunized only or treated with antifungal
drugs. An additive protective effect of P10 and antifungal
drugs was observed. In the group of mice treated with sulfa-
methoxazole, an early protection was followed by relapse,
although the group with associated sulfamethoxazole and
P10 vaccination succeeded in controlling the disease (Fig. 1). The
combination of drugs and P10 led to increased protection as
FIG. 3. Additive effect of P10 immunization and trimethoprim-sulfamethoxazole treatment, after 120 days, in mice intratracheally infected
under protocol 2 (treatment after 30 days of infection). (A) Lung section from untreated mouse; (B) lung section from mouse immunized with P10;
(C) lung section from mouse treated with trimethoprim-sulfamethoxazole; (D) apparently resolved granulomas, with very few fungal cells, in lung
section of mouse subjected to P10 immunization and drug treatment. Three hundred microscopic fields for all four groups were analyzed, with the
following results: group A, granulomas with yeasts, 24%, and noninflamed areas, 27%; group B, granulomas with yeasts, 15%, and noninflamed
areas, 46%; group C, granulomas with yeasts, 32%, and noninflamed areas, 26%; group D, granulomas with yeasts, 12%, and noninflamed areas,
55%. Statistically significant differences (P  0.05) were observed for P10-treated groups. Gomori silver staining was used; magnification, 25.
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reflected in organ histological areas with very few or undetect-
able yeast cells.
With protocol 2, we aimed at reproducing the situation of
established infection. The fungal burden was examined after
60 and 120 days of infection. The pattern of CFU in organs
showed an additive effect of P10 immunization and drug
treatment at 60 and 120 days after infection, with 60 to 80%
reduction of lung CFU compared with controls (untreated
infected animals or those that received only CFA). P10
immunization or chemotherapy separately achieved 40 to
60% reduction of CFU; administration of P10 together with
the drug fully controlled the “relapsing” effect (Fig. 2).
Histopathology showed large preserved areas in the lung
and very few yeast cells. In Fig. 3 (protocol 2), we show the
lung histopathology of a mouse treated with sulfa-derived
drugs alone and combined with P10 vaccination. Clearly,
P10 vaccination was the essential adjuvant therapy to con-
tain the infection.
P10 activates a Th-1 immune response with a known pattern
of cytokine production in vitro and in vivo (10). First, we
studied the cytokine levels in the lungs of mice after 48 h of
infection. Even though a few results were not statistically sig-
nificant, a pattern was clearly defined. At 30 days no changes in
cytokine levels were observed in drug-treated groups of mice in
combination or not with P10. After 90 days, however, there was
a consistent decrease of interleukin-4 (IL-4) and IL-10 and an
increase of gamma interferon (IFN-) in drug-treated animals
also immunized with P10 in relation to mice treated with drugs
only (Table 1). In relation to controls, no differences were seen
between sham infection and the group that received only ad-
juvant. Animals that were only infected or only immunized
with P10 showed increased levels of both type 1 and type 2
cytokines (Table 1).
In animals with established infection, sham- and adjuvant-
treated groups of mice did not show differences, whereas the
group infected with P. brasiliensis but untreated showed
increased production of IL-4, IL-10, IL-12, and IFN-. P10
immunization promoted even higher levels of IL-12 and
IFN- but decreased concentrations of IL-4 and IL-10. Drug
treatment generally stimulated IL-4 and IL-10 cytokines
compared to the case for the untreated infected group. The
combination with P10 immunization showed, in general, in-
creased production of IL-12 and IFN- and reduction of
IL-4 and IL-10, with little exception (Table 2). Thus, al-
though both Th-1 and Th-2 cellular immune responses were
present in all cases, drug treatment either had little influ-
ence or caused an increase in the Th-2 response, possibly
correlated with increased destruction of fungal cells. The
least effective chemotherapy, with trimethoprim-sulfameth-
oxazole, which allowed a late relapsing infection, doubled
the production of IL-4 and IL-10 and had little effect on
IL-12 and IFN-. Association with P10 greatly stimulated a
Th-1 response with increased production of IL-12 and
IFN-, clearly leading to protection.
Several features have been examined for validation of P10
as a candidate vaccine, including (i) the presentation of P10
by different mouse haplotypes (10); (ii) conservation in na-
ture, determined by examining gp43 molecules from differ-
ent isolates (1); (iii) immunogenicity in constructions that
do not require complete Freund’s adjuvant (6, 11); (iv)
presentation by a large number of human HLA-DR mole-
cules, more than that for other promiscuous peptides de-
rived from gp43 (2); and (v) its role in the immunoprotec-
tion of mice infected with P. brasiliensis and subjected to
chemotherapy, which was the focus of the present work. The
data obtained strongly suggest that a P10-based vaccine
should be used to improve chemotherapy, reduce treatment
time, and prevent relapsing disease.
TABLE 2. Cytokine levels in lungs of mice infected and subjected to chemotherapy and/or P10 vaccination after 30 days of infection
Treatment group
Cytokine level (pg/ml) at the indicated time (days) of infectiona
IL-4 IL-10 IL-12 IFN-
60 120 60 120 60 120 60 120
Sham 752  78 845  85 4,680  511 3,852  665 13,211  958 11,789  1,214 712  222 648  65
Adjuvant 988  111 854  70 4,997  488 4,221  326 15,021  1,012 10,121  1,014 911  111 914  102
Untreated 2,654  112 2,312  522 16,021  612 10,520  1,584 38,021  1,562 29,522  2,011 2,615  214 3,852  545
P10 1,510  88 1,121  232 11,115  522 6,250  1,128 78,521  2,123 63,160  3,602 5,741  612 6,412  1,369
Fluconazole 3,120  166# 3,321  665# 24,021  1,021# 27,321  2,358# 59,564  1,855 63,555  4,312 2,985  251 3,621  511
Fluconazole  P10 1,712  98 2,011  501 14,333  633 22,619  1,545 77,512  2,213* 88,888  3,101* 6,021  452* 9,021  741*
Ketoconazole 5,312  615# 3,842  852# 26,313  1,245# 14,222  2,354# 45,326  2,651 52,321  2,988 3,011  365 2,014  636
Ketoconazole  P10 3,021  188 2,011  654 20,231  999 11,050  1,655 76,582  2,365* 56,500  4,021* 7,112  522* 8,844  766*
Itraconazole 3,011  318 3,015  925# 19,744  823# 17,455  2,011# 59,621  1,025 54,114  3,022 2,744  329 2,113  527
Itraconazole  P10 2,633  215 1,855  357 13,212  655 11,456  1,045 79,625  1,653* 44,112  2,958 6,623  444* 9,571  1,712*
Amphotericin B 1,546  274 1,879  603 17,100  555# 14,101  1,789 33,265  2,012 44,101  3,012 3,111  363 4,511  951
Amphotericin B  P10 1,115  63 2,011  518 11,011  456 13,011  1,412 68,222  2,322* 64,111  5,114* 7,751  454* 6,255  1,874*
Trimethoprim-
sulfamethoxazole
5,311  512# 5,845  1,232# 23,121  1,066# 21,456  1,654# 33,665  1,988 38,258  2,145 2,655  388 2,487  358
Trimethoprim-
sulfamethoxazole  P10
2,955  311 3,695  989 15,321  633 14,258  1,658 69,852  2,011* 60,115  2,532* 5,111  522* 10,421  654*
a Boldface indicates a predominat Th-1 or Th-2-like response according to the cytokines produced (IL-12/IFN- or IL-4/IL-10, respectively). *, statistically significant
difference (P  0.05) relative to mice treated only with the drug; #, statistically significant difference (P  0.05) relative to mice immunized with P10 and treated with
the drug. Values are means  standard deviations of measurements from 5 to 10 animals in each group. The whole experiment was repeated twice with reproducible
results.
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